Fexuprazan vs esomeprazole for endoscopic submucosal dissection-induced gastric ulcer healing: A double-blind randomized controlled trial

Table 2 Ulcer healing and shrinkage rate after endoscopic submucosal dissection in the per-protocol population, n (%)/median (interquartile range)

Variables	Fexuprazan 40 mg (n = 51)	Esomeprazole 40 mg (n = 56)	P value
Primary endpoint
Complete healing (100%)	46 (90.2)	42 (75.0)	0.040
Risk difference (95%CI)	15.2 (1.2-29.2)
Secondary endpoints
8-week shrinkage rate	100 (100-100)	97.72 (96.54-100)	0.049
4-week shrinkage rate	95.92 (92-98.53)	93.48 (88.69-97.36)	0.049
Healing stage at 4 weeks			0.464
Active (A1, A2)	3 (5.9)	1 (1.8)
Healing (H1, H2)	42 (82.4)	50 (89.3)
Scar (S1, S2)	6 (11.8)	5 (8.9)
Healing stage at 8 weeks			0.040
Active (A1, A2)	0 (0.0)	0 (0.0)
Healing (H1, H2)	5 (9.8)	14 (25.0)
Scar (S1, S2)	46 (90.2)	42 (75.0)

CI: Confidence interval.